NLS Pharmaceutics AG Appoints CBIZ as New Auditor Amid Internal Control Weaknesses
Reuters
Sep 23
NLS Pharmaceutics AG Appoints CBIZ as New Auditor Amid Internal Control Weaknesses
NLS Pharmaceutics AG has announced a change in its independent registered public accounting firm following the acquisition of Marcum LLP's attestation business by CBIZ CPAs P.C. As of September 17, 2025, Marcum LLP resigned as the company's auditor, and CBIZ was engaged to take over the role for the fiscal year ending December 31, 2025. The transition was approved by the Audit Committee of NLS Pharmaceutics' Board of Directors. Notably, Marcum's report on the company's financial statements for the fiscal year ended December 31, 2024, did not contain any adverse opinions or disclaimers but did highlight substantial doubt about the company's ability to continue as a going concern. Additionally, the company disclosed material weaknesses in its internal control over financial reporting, specifically related to a lack of trained accounting professionals and insufficient segregation of duties.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-089523), on September 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.